Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein but not α-fetoprotein as a Long-Term Hepatocellular Carcinoma Predictor.
Aged
Antigens, Neoplasm
/ blood
Antiviral Agents
/ therapeutic use
Biomarkers
/ blood
Biomarkers, Tumor
/ blood
Carcinoma, Hepatocellular
/ blood
Female
Humans
Liver Neoplasms
/ blood
Male
Middle Aged
Plant Lectins
/ metabolism
Receptors, N-Acetylglucosamine
/ metabolism
Sustained Virologic Response
alpha-Fetoproteins
/ analysis
AFP
WFA±M2BP
chronic hepatitis C
direct-acting antivirals
hepatocellular carcinoma
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
21 May 2020
21 May 2020
Historique:
received:
11
05
2020
revised:
18
05
2020
accepted:
19
05
2020
entrez:
28
5
2020
pubmed:
28
5
2020
medline:
17
2
2021
Statut:
epublish
Résumé
Identification of high-risk patients for hepatocellular carcinoma (HCC) after sustained virological responses (SVR) is necessary to define candidates for long-term surveillance. In this study, we examined whether serum markers after 1 year of SVR could predict subsequent HCC development. Total 734 chronic hepatitis C patients without a history of HCC who achieved SVR with direct-acting antivirals were included. The regular surveillance for HCC started from 24 weeks after the end of treatment (SVR24). Factors at SVR24 and 1 year after SVR24 were analyzed for predicting HCC development. During the mean observation period of 19.7 ± 10 months, 24 patients developed HCC. At SVR24,
Identifiants
pubmed: 32455631
pii: ijms21103640
doi: 10.3390/ijms21103640
pmc: PMC7279305
pii:
doi:
Substances chimiques
Antigens, Neoplasm
0
Antiviral Agents
0
Biomarkers
0
Biomarkers, Tumor
0
LGALS3BP protein, human
0
Plant Lectins
0
Receptors, N-Acetylglucosamine
0
alpha-Fetoproteins
0
wisteria lectin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Agency for Medical Research and Development
ID : JP19fk0210025h0003
Déclaration de conflit d'intérêts
All authors have no conflict of interest to disclose.
Références
J Hepatol. 2018 Mar;68(3):606-607
pubmed: 29079286
J Gastroenterol. 2014 Jul;49(7):1152-62
pubmed: 23860735
Hepatol Res. 2015 Jan;45(2):
pubmed: 25625806
Gastroenterology. 2017 Oct;153(4):996-1005.e1
pubmed: 28642197
Hepatol Res. 2016 Jul;46(8):734-42
pubmed: 26508201
J Gastroenterol. 2017 Oct;52(10):1122-1129
pubmed: 28315983
Sci Rep. 2013;3:1065
pubmed: 23323209
J Viral Hepat. 2019 Jul;26(7):893-899
pubmed: 30974045
Hepatol Res. 2015 Oct;45(10):E82-8
pubmed: 25559682
J Gastroenterol. 2014 Nov;49(11):1495-503
pubmed: 24337828
J Viral Hepat. 2013 Jan;20(1):72-6
pubmed: 23231087
Ann Intern Med. 2000 Apr 4;132(7):517-24
pubmed: 10744587
Hepatol Int. 2018 Jul;12(4):356-367
pubmed: 30030720
Hepatol Res. 2018 Dec;48(13):1131-1139
pubmed: 30030872
Hepatol Res. 2018 Aug;48(9):746-756
pubmed: 29480939
Hepatology. 2013 Oct;58(4):1253-62
pubmed: 23564522
J Gastroenterol. 2018 Oct;53(10):1142-1150
pubmed: 29626296
Hepatology. 2018 Jan;67(1):401-421
pubmed: 28859233
Hepatol Res. 2017 Sep;47(10):1021-1031
pubmed: 27859993
J Hepatol. 2017 Nov;67(5):933-939
pubmed: 28627363
Radiographics. 2017 Nov-Dec;37(7):1994-2017
pubmed: 29131761
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Hepatol Res. 2019 May;49(5):570-578
pubmed: 30623521
Gastroenterology. 2019 Nov;157(5):1264-1278.e4
pubmed: 31356807
Aliment Pharmacol Ther. 2018 Sep;48(6):664-670
pubmed: 30047149
Hepatol Res. 2019 Mar;49(3):264-270
pubmed: 30171740
Clin Gastroenterol Hepatol. 2019 Nov;17(12):2616-2618
pubmed: 30502507
Hepatol Res. 2018 Jun;48(7):529-538
pubmed: 29316051